Skip to content
Screener

Halozyme Therapeutics HALO D&A

D&A at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$46.2M+11.6%
Opko Health logo
Opko HealthOPK
$18.97M-2.4%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$700K+17.1%
Arrowhead Research logo
Arrowhead ResearchARWR
$6.37M+4.7%
Amgen logo
AmgenAMGN
$1.11B-17.1%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$9.91B+36.0%
Enterprise value$11.93B+36.1%
P/E13.8×-3.9×
P/S6×-0.2×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104

FAQ

What is Halozyme Therapeutics's D&A?
Halozyme Therapeutics (HALO) reported D&A of $4.5M in Q2 2026.
How has Halozyme Therapeutics's D&A changed year-over-year?
Halozyme Therapeutics's D&A increased by 66.7% year-over-year, from $2.7M to $4.5M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Halozyme Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude